A Broad-Spectrum Antiviral Targeting High-Impact RNA Viruses
A clinical-stage antiviral with demonstrated activity across more than 20 RNA viruses, supported by significant prior investment and a strategic regulatory pathway.
20+
RNA Viruses Targeted
100%
Survival in Marburg & Ebola Primate Studies
US$70M+
Prior U.S. Government Funding
KEY HIGHLIGHTS
Targeting Viral Replication Across RNA Virus Families
Galidesivir is a differentiated antiviral candidate targeting a core viral replication mechanism shared across RNA viruses. With demonstrated preclinical efficacy, extensive prior investment and a defined regulatory pathway, it represents a strategically positioned program within Island Pharmaceuticals’ pipeline.
Introduction
Galidesivir’s ability to target multiple virus families positions it as a valuable asset in addressing both current and emerging infectious diseases.
Supported by over US$70 million in funding from the U.S. government, the program has been extensively developed and is recognised for its potential role in global biodefence and pandemic preparedness initiatives.
MECHANISM OF ACTION
Galidesivir is a nucleoside analog that mimics adenosine triphosphate (ATP), allowing it to inhibit viral RNA synthesis. By interfering with RNA-dependent RNA polymerase, the drug disrupts a fundamental process required for viral replication.
Because mechanism is shared across many RNA viruses, Galidesivir has the potential to deliver broad antiviral activity across multiple high-impact indications, rather than targeting a single virus.
PRECLINICAL EVIDENCE
Preclinical studies have demonstrated compelling efficacy across high-consequence viral infections.
In non-human primate models, Galidesivir achieved 100% survival in subjects challenged with Marburg or Ebola viruses when treatment was administered shortly after infection.
These findings highlight its potential as a rapid-response therapeutic in severe and often fatal viral diseases.
DEVELOPMENT & STRATEGIC POSITIONING
Island Pharmaceuticals is advancing Galidesivir as part of its focused strategy to address infectious diseases with significant unmet need. The program builds on prior development by BioCryst Pharmaceuticals and is supported by substantial historical investment and government backing.
By progressing Galidesivir within a modern clinical and regulatory framework, Island is seeking to unlock its potential across multiple high-impact indications, particularly within the biodefence landscape.
REGULATORY PATHWAY
Galidesivir may be eligible for development under the FDA’s Animal Rule, a pathway designed for therapies targeting high-risk pathogens where human efficacy trials are not feasible.
This provides a potential route to accelerated approval in indications such as Marburg, where traditional clinical trial design presents significant ethical and practical challenges.
ROLE IN GLOBAL HEALTH PREPAREDNESS
Broad-spectrum antivirals such as Galidesivir are increasingly recognised as critical tools in global outbreak response.
Unlike pathogen-specific treatments, these therapies have the potential to be deployed early—before a specific virus is identified—helping to contain spread and reduce mortality during emerging outbreaks. This positions Galidesivir not only as a clinical-stage asset, but as part of a broader strategic response to future pandemic and biodefence threats.
By progressing Galidesivir within a modern clinical and regulatory framework, Island is seeking to unlock its potential across multiple high-impact indications, particularly within the biodefence landscape.